Pfizer beats by $0.10, reports revs in-line; raises FY19 EPS in-line, reaffirms FY19 revs guidance (39.59)
- Reports Q1 (Mar) earnings of $0.85 per share, excluding non-recurring items, $0.10 better than the S&P Capital IQ Consensus of $0.75; revenues rose 1.6% year/year to $13.12 bln vs the $13.01 bln S&P Capital IQ Consensus.
- Co issues guidance for FY19, raises EPS to $2.83-2.93 from $2.82-2.92, excluding non-recurring items, vs. $2.89 S&P Capital IQ Consensus; reaffirms FY19 revs of $52.0-54.0 bln vs. $53.43 bln S&P Capital IQ Consensus